Abstract
In most patients with acute or chronic liver failure, extensive changes in all pathways contributing to hemostasis are found. These hemostatic alterations concern both pro- and antihemostatic pathways, and therefore the net result of the hemostatic dysbalance is unclear. Although it is generally believed that patients with liver disease have a hemostasis-related bleeding tendency, this concept is challenged in recent literature. Although the bleeding problems in patients with liver disease are obvious, the clinically most relevant bleeding episodes, i.e., bleeding from ruptured varices or ulcers, are due to vascular abnormalities and portal hypertension, and not to an abnormal hemostatic system. Moreover, patients with liver disease sometimes experience thrombosis of the portal vein or hepatic artery, which is in part attributed to hypercoagulation. In addition, a substantial part of the patients with liver disease undergoing liver transplantation can nowadays undergo this major surgical procedure, which involves significant hemostatic challenges, without transfusion of blood products. Therefore, the recent debate on the presence of a major hemostatic defect in patients with liver disease seems justified. This paper will review the hemostatic changes that occur in acute and chronic liver failure, and will review hemostasis testing and reversal of coagulopathy in these patients.
References
1.
Aster RH: Pooling of platelets in the spleen: role in the pathogenesis of ‘hypersplenic’ thrombocytopenia. J Clin Invest 1966;45:645–657.
2.
Goulis J, Chau TN, Jordan S, Mehta AB, Watkinson A, Rolles K, Burroughs AK: Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999;44:754–758.
3.
Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y, Kuwana M: A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003;37:1267–1276.
4.
Levine RF, Spivak JL, Meagher RC, Sieber F: Effect of ethanol on thrombopoiesis. Br J Haematol 1986;62:345–354.
5.
Ben Ari Z, Osman E, Hutton RA, Burroughs AK: Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999;94:2977–2982.
6.
Escolar G, Cases A, Vinas M, Pino M, Calls J, Cirera I, Ordinas A: Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999;84:614–619.
7.
Laffi G, Marra F, Gresele P, Romagnoli P, Palermo A, Bartolini O, Simoni A, Orlandi L, Selli ML, Nenci GG: Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992;103:641–646.
8.
Laffi G, Marra F, Failli P, Ruggiero M, Cecchi E, Carloni V, Giotti A, Gentilini P: Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. Gastroenterology 1993;105:148–156.
9.
Laffi G, Cominelli F, Ruggiero M, Fedi S, Chiarugi VP, La Villa G, Pinzani M, Gentilini P: Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988;8:1620–1626.
10.
Pasche B, Ouimet H, Francis S, Loscalzo J: Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994;83:404–414.
11.
Desai K, Mistry P, Bagget C, Burroughs AK, Bellamy MF, Owen JS: Inhibition of platelet aggregation by abnormal high density lipoprotein particles in plasma from patients with hepatic cirrhosis. Lancet 1989;1:693–695.
12.
Turitto VT, Baumgartner HR: Platelet interaction with subendothelium in a perfusion system: physical role of red blood cells. Microvasc Res 1975;9:335–344.
13.
Cahill PA, Redmond EM, Sitzmann JV: Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001;89:273–293.
14.
Lisman T, Adelmeijer J, de Groot PG, Janssen HL, Leebeek FW: No evidence for an intrinsic platelet defect in patients with liver cirrhosis – studies under flow conditions. J Thromb Haemost 2006;4:2070–2072.
15.
Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell’era A, Fabris F, Salerno F, Mannucci PM: Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006;44:440–445.
16.
Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, Violi F: High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996;23:1377–1383.
17.
Hollestelle MJ, Geertzen HGM, Straatsburg IH, van Gulik TM, van Mourik JA: Factor VIII expression in liver disease. Thromb Haemost 2004;91;267–275.
18.
Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW: Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006;44:53–61.
19.
Blanchard RA, Furie BC, Jorgensen M, Kruger SF, Furie B: Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981;305:242–248.
20.
Martinez J, MacDonald KA, Palascak JE: The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983;61:1196–1202.
21.
Bontempo FA, Lewis JH, Gorenc TJ, Spero JA, Ragni MV, Scott JP, Starzl TE: Liver transplantation in hemophilia A. Blood 1987;69:1721–1724.
22.
Hollestelle MJ, Poyck PP, Hollestelle JM, Marsman HA, Mourik JA, Gulik TM: Extrahepatic factor VIII expression in porcine fulminant hepatic failure. J Thromb Haemost 2005;3:2274–2280.
23.
Jacquemin M, Neyrinck A, Hermanns MI, Lavend’homme R, Rega F, Saint-Remy JM, Peerlinck K, Van RD, Kirkpatrick CJ: FVIII production by human lung microvascular endothelial cells. Blood 2006;108:515–517.
24.
Lisman T, Leebeek FWG, de Groot PG: Haemostatic abnormalities in patients with liver disease. J Hepatol 2002;37:280–287.
25.
Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP: Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990;87:8869–8873.
26.
Oksuzoglu G, Simsek H, Haznedaroglu IC, Kirazli S: Tissue factor pathway inhibitor concentrations in cirrhotic patients with and without portal vein thrombosis. Am J Gastroenterol 1997;92:303–306.
27.
Stein SF, Harker LA: Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982;99:217–230.
28.
Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, de Groot PG: Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001;121:131–139.
29.
Biland L, Duckert F, Prisender S, Nyman D: Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thromb Haemost 1978;39:646–656.
30.
Leiper K, Croll A, Booth NA, Moore NR, Sinclair T, Bennett B: Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease. J Clin Pathol 1994;47:214–217.
31.
Leebeek FWG, Kluft C, Knot EAR, de Maat MPM, Wilson JHP: A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991;101:1382–1390.
32.
Pernambuco JR, Langley PG, Hughes RD, Izumi S, Williams R: Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology 1993;18:1350–1356.
33.
Leebeek FWG: Hyperfibrinolysis in liver cirrhosis; in Greenwaldt P (ed): Fibrinolysis in Disease. Boca Raton, CRC Press, 1995, pp 194–201.
34.
Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, Balsano F, the CALC Group: Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology 1993;17:78–83.
35.
Oka K, Tanaka K: Intravascular coagulation in autopsy cases with liver diseases. Thromb Haemost 1979;42:564–570.
36.
Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P: Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003;38:230–237.
37.
Segal H, Cottam S, Potter D, Hunt BJ: Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997;25:683–688.
38.
Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D’Andrea G, Marmo R, Ames PR, Balzano A: Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000;31:345–348.
39.
Joist JH, George JN: Hemostatic abnormalities in liver and renal disease; in Colman RW, Hirsh J, Marder VJ, Clowes AE, George JN (eds): Hemostasis and Thrombosis. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 955–973.
40.
Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK: Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005;54:556–563.
41.
Reitsma PH, Branger J, Van Den BB, Weijer S, van der PT, Meijers JC: Procoagulant protein levels are differentially increased during human endotoxemia. J Thromb Haemost 2003;1:1019–1023.
42.
Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A, Sanyal AJ: Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006;44:1039–1046.
43.
Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannucci PM: Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005;41:553–558.
44.
Mannucci PM: Abnormal hemostasis tests and bleeding in chronic liver disease: Are they related? No. J Thromb Haemost 2006;4:721–723.
45.
Lisman T, Caldwell SH, Leebeek FWG, Porte RJ: Hemostasis in chronic liver disease – Is chronic liver disease associated with a bleeding diathesis? J Thromb Haemost 2006;4:2059–2060.
46.
Sharara AI, Rockey DC: Gastroesophageal variceal hemorrhage. N Engl J Med 2001;345:669–681.
47.
De Boer MT, Molenaar IQ, Hendriks HG, Slooff MJ, Porte RJ: Minimizing blood loss in liver transplantation: progress through research and evolution of techniques. Dig Surg 2005;22:265–275.
48.
Trotter JF, Brimhall B, Arjal R, Phillips C: Specific laboratory methodologies achieve higher model for end-stage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004;10:995–1000.
49.
Robert A, Chazouilleres O: Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996;24:1392–1394.
50.
O’Shaughnessy DF, Atterbury C, Bolton MP, Murphy M, Thomas D, Yates S, Williamson LM: Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126:11–28.
51.
Youssef WI, Salazar F, Dasarathy S, Beddow T, Mullen KD: Role of fresh-frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 2003;98:1391–1394.
52.
Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Engl J Med 2001;344:495–500.
53.
Burroughs AK, Matthews K, Qadiri M, Thomas N, Kernoff P, Tuddenham E, McIntyre N: Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) 1985;291:1377–1381.
54.
De Franchis R, Arcidiacono PG, Carpinelli L, Andreoni B, Cestari L, Brunati S, Zambelli A, Battaglia G, Mannucci PM: Randomized controlled trial of desmopressin plus terlipressin versus terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. Hepatology 1993;18:1102–1107.
55.
Wong AY, Irwin MG, Hui TW, Fung SK, Fan ST, Ma ES: Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth 2003;50:14–20.
56.
Pivalizza EG, Warters RD, Gebhard R: Desmopressin before liver transplantation. Can J Anaesth 2003:50:748–749.
57.
Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, Palareti G, Hermans J, Terpstra OT: Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 2000;355:1303–1309.
58.
Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, Roger SL, Glynn MF: Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996;85:1043–1048.
59.
Mangano DT, Tudor IC, Dietzel C: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353–365.
60.
Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, Hagenaars AJ, Melsen T, Slooff MJ, van der Meer J: Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001;71:402–405.
61.
Planinsic RM, van der MJ, Testa G, Grande L, Candela A, Porte RJ, Ghobrial RM, Isoniemi H, Schelde PB, Erhardtsen E, Klintmalm G, Emre S: Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005;11:895–900.
62.
Lodge JP, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S, Garcia-Valdecasas JC, McAlister V, Mirza DF: Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005;11:973–979.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
